Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tolazoline is a non-selective competitive alpha-adrenergic receptor antagonist and vasodilator primarily used to treat spasms of peripheral blood vessels and persistent pulmonary hypertension of the newborn. It acts by directly relaxing vascular smooth muscle, leading to decreased total peripheral resistance and increased cardiac output. Tolazoline exhibits moderate alpha-adrenergic blocking activity (antagonist at both alpha-1 and alpha-2 adrenergic receptors) as well as histamine agonist activity at H1 and H2 receptors. Its therapeutic effects are mediated through both direct action on blood vessels and indirect effects via release of endogenous histamine. In veterinary medicine, it is commonly used to reverse xylazine-induced sedation[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tolazoline.